AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38452779 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly primaquine 0.75 mg/kg for 8 weeks
Number of subjects: 5554
Study 38452779 — intervention group
Group type: COMPARATOR
Intervention: Tafenoquine (n=2134)
Number of subjects: 5554
Study 38452779 — intervention group
Group type: COMPARATOR
Intervention: 7-day primaquine (n=370)
Number of subjects: 5554
Study 38452779 — intervention group
Group type: COMPARATOR
Intervention: Tafenoquine
Number of subjects: 5554
Study 38452779 — intervention group
Group type: COMPARATOR
Intervention: 7-day primaquine
Number of subjects: 5554
Study 38452784 — intervention group
Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB)
Number of subjects: 253
Study 38452784 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 253
Study 38452788 — intervention group
Group type: EXPERIMENTAL
Intervention: ASTX727 (cedazuridine 100 mg and decitabine 35 mg) plus venetoclax 400 mg
Number of subjects: 62
Study 38453176 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib and letrozole
Number of subjects: 40
Study 38453202 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention (12-week intervention comprising physical activity, nutrition, and breathing/relaxation delivered through a mobile application).
Number of subjects: 88
Study 38453202 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention (12-week intervention).
Number of subjects: 88
Study 38453202 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 88
Study 38453208 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based mobile-guided exercise-based cardiac rehabilitation for 3 months
Number of subjects: 90
Study 38453411 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D measurements
Number of subjects: 31
Study 38453411 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-volume measurements
Number of subjects: 31
Study 38453411 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid volume change measurements
Number of subjects: 31
Study 38453411 — intervention group
Group type: COMPARATOR
Intervention: Comparison of volumetric and 2D measurements
Number of subjects: 31
Study 38453435 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-505 2.25 g/day
Number of subjects: 158
Study 38453435 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-505 1.50 g/day
Number of subjects: 158
Study 38453435 — intervention group
Group type: EXPERIMENTAL
Intervention: VS-505 4.50 g/day
Number of subjects: 158
Study 38453435 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer carbonate 4.80 g/day
Number of subjects: 158
Study 38453677 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine (placebo-controlled, randomized, double-blind clinical trial)
Number of subjects: 144
Study 38453781 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP2A+ group received FEC100 for 3 cycles followed by 3 cycles of Trastuzumab (8 mg/kg then 6 mg/kg), Pertuzumab (840 mg/kg then 420 mg/kg), and Docetaxel (75 mg/m2).
Number of subjects: 74
Study 38453781 — intervention group
Group type: COMPARATOR
Intervention: TOP2A- group received the same chemotherapy regimen as TOP2A+ group.
Number of subjects: 74
Study 38453781 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP2A+ group received the same chemotherapy regimen as TOP2A- group.
Number of subjects: 74
Study 38454079 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Number of subjects: 278
Study 38454079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 278
Study 38454079 — intervention group
Group type: COMPARATOR
Intervention: Switch to venlafaxine XR or duloxetine
Number of subjects: 278
Study 38454126 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-13Rα2-targeted CAR-T cells via dual ICT/ICV delivery
Number of subjects: 65
Study 38454132 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 292
Study 38454421 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable plaques
Number of subjects: 182
Study 38454421 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable plaques
Number of subjects: 182
Study 38454421 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group (immunohistochemistry analysis)
Number of subjects: 182
Study 38454451 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus gemcitabine and oxaliplatin (GEMOX)
Number of subjects: 42
Study 38454451 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus GEMOX
Number of subjects: 42
Study 38454468 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) - five cycles every other day
Number of subjects: 66
Study 38454468 — intervention group
Group type: COMPARATOR
Intervention: Sham apheresis (control)
Number of subjects: 66
Study 38454468 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 66
Study 38454482 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional DNase levels in severe patients
Number of subjects: 145
Study 38454482 — intervention group
Group type: EXPERIMENTAL
Intervention: DNase1 antigen levels
Number of subjects: 145
Study 38454482 — intervention group
Group type: EXPERIMENTAL
Intervention: DNase1L3 antigen levels
Number of subjects: 145
Study 38454482 — intervention group
Group type: EXPERIMENTAL
Intervention: DNASE1 polymorphisms
Number of subjects: 145
Study 38454482 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmacytoid dendritic cells (pDCs)
Number of subjects: 145
Study 38454482 — intervention group
Group type: EXPERIMENTAL
Intervention: DNase administration
Number of subjects: 145
Study 38454501 — intervention group
Group type: EXPERIMENTAL
Intervention: SEARCH-IPT intervention (collaborative groups of district health managers, leadership and management training over 3 years)
Number of subjects: 0
Study 38454501 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 0
Study 38455033 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended preconception lifestyle programme (PreLiFe-programme) including a mobile application with tailored advice and skills training on diet, physical activity, and mindfulness, combined with motivational interviewing over the telephone.
Number of subjects: 211
Study 38455033 — intervention group
Group type: COMPARATOR
Intervention: Attention control arm receiving treatment information by mobile phone in addition to standard care.
Number of subjects: 211
Study 38455366 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemay022 at doses of 50-600 mg QD and 300 mg BID
Number of subjects: 28
Study 38455850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 500 mg tablets, three times per day (total dose of 1500 mg/day) for eight weeks
Number of subjects: 60
Study 38455850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 38455935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional survey with questionnaire and physical measurements
Number of subjects: 2100
Study 38455935 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological, genetic and microbiological analyses
Number of subjects: 2100
Study 38455935 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of genomic data combined with anthropological data
Number of subjects: 2100
Study 38455948 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge risk prediction algorithms for mother-newborn dyads
Number of subjects: 7000
Study 38455948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction models for maternal outcomes
Number of subjects: 7000
Study 38455948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction models for newborn outcomes
Number of subjects: 7000
Study 38456042 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment linkage strategies
Number of subjects: 0
Study 38456291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (2 × 12 mg)
Number of subjects: 50
Study 38456291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 50
Study 38456289 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive speckle-tracking echocardiography with passive leg raise maneuver
Number of subjects: 3285
Study 38456289 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire
Number of subjects: 3285
Study 38456289 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 3285
Study 38456289 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial stiffness assessment
Number of subjects: 3285
Study 38456289 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomics (including NT-proBNP)
Number of subjects: 3285
Study 38456289 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic indices
Number of subjects: 3285
Study 38456441 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu-Chek Solo micropump system (Solo)
Number of subjects: 181
Study 38456441 — intervention group
Group type: COMPARATOR
Intervention: Multiple Daily Injections (MDI)
Number of subjects: 181
Study 38456441 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipod
Number of subjects: 181
Study 38456438 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT (high-sensitivity cardiac troponin T) levels
Number of subjects: 385
Study 38456561 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-minute immersive simulation training
Number of subjects: 40
Study 38456561 — intervention group
Group type: COMPARATOR
Intervention: Online educational training (control)
Number of subjects: 40
Study 38456620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 332
Study 38456620 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 332
Study 38456620 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 332
Study 38456636 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program (individual four face-to-face and six online education sessions)
Number of subjects: 52
Study 38456636 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 52
Study 38456660 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax (250 mg daily days 1 to 28) and Trametinib (2 mg daily days 1 to 14)
Number of subjects: 91
Study 38456660 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax and Trametinib
Number of subjects: 91
Study 38456703 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose CoronaVac
Number of subjects: 55
Study 38456703 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 55
Study 38456705 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 1204
Study 38456705 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 1204
Study 38456874 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge GDMT prescription after CABG surgery
Number of subjects: 968
Study 38456874 — intervention group
Group type: COMPARATOR
Intervention: Discharge GDMT prescription
Number of subjects: 968
Study 38456888 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) deactivated in a home setting and reactivated when pain returned.
Number of subjects: 158
Study 38456888 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) with back pain as primary indication, high-frequency stimulation, and higher pain score at deactivation.
Number of subjects: 158
Study 38456933 — intervention group
Group type: EXPERIMENTAL
Intervention: Dragon Boat activity
Number of subjects: 31
Study 38456933 — intervention group
Group type: COMPARATOR
Intervention: Home-based non-supervised training program (Control)
Number of subjects: 31
Study 38457041 — intervention group
Group type: EXPERIMENTAL
Intervention: Single hem-o-lok clips
Number of subjects: 294
Study 38457041 — intervention group
Group type: COMPARATOR
Intervention: Double hem-o-lok clips
Number of subjects: 294
Study 38457151 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait-prioritization (GP) strategy
Number of subjects: 34
Study 38457151 — intervention group
Group type: COMPARATOR
Intervention: Manual-prioritization (MP) strategy
Number of subjects: 34
Study 38457175 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative experiences after mastectomy (including lymphedema, phantom breast sensations, persistent chronic pain, changes in body image and sexuality)
Number of subjects: 23
Study 38457175 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative experiences after mastectomy
Number of subjects: 23
Study 38457175 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about sexuality from healthcare professionals
Number of subjects: 23
Study 38457175 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up period after mastectomy
Number of subjects: 23
Study 38457175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-patient dialogue regarding hospitalization and sexuality
Number of subjects: 23
Study 38457177 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid-fortified iodized salt (300 µg/d of folic acid)
Number of subjects: 83
Study 38457177 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 83
Study 38457203 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Management for You (OPY) tool - social influence version
Number of subjects: 0
Study 38457203 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Management for You (OPY) tool - precommitment version
Number of subjects: 0
Study 38457203 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Management for You (OPY) tool - testimonial version
Number of subjects: 0
Study 38457203 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 38457202 — intervention group
Group type: EXPERIMENTAL
Intervention: Suubi-Mhealth intervention
Number of subjects: 0
Study 38457202 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 38457361 — intervention group
Group type: EXPERIMENTAL
Intervention: NL-ratio (neutrophil-to-lymphocytes ratio) > 2.44
Number of subjects: 1022
Study 38457361 — intervention group
Group type: EXPERIMENTAL
Intervention: NL-ratio (tenth decile > 3.53)
Number of subjects: 1022
Study 38457361 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-ratio (monocytes-to-lymphocytes ratio) (tenth decile > 2.02)
Number of subjects: 1022
Study 38457359 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD <0.1% at end of induction (EOI)
Number of subjects: 209
Study 38457359 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD ≥0.1% at end of induction (EOI)
Number of subjects: 209
Study 38457359 — intervention group
Group type: COMPARATOR
Intervention: Cox regression for EFS using arm A as reference
Number of subjects: 209
Study 38457359 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 209
Study 38457759 — intervention group
Group type: EXPERIMENTAL
Intervention: Lugol's chromoendoscopy (screening group)
Number of subjects: 33847
Study 38457759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 33847
Study 38457761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 559
Study 38457761 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 559
Study 38458016 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention consisting of weekly one-hour sessions combining heart rate variability and temperature biofeedback for six weeks.
Number of subjects: 20
Study 38458016 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback intervention
Number of subjects: 20
Study 38458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group A (PIK3CA alterations)
Number of subjects: 87
Study 38458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group B (cell cycle pathway alterations)
Number of subjects: 87
Study 38458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group C (no druggable genetic alterations)
Number of subjects: 87
Study 38458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group A
Number of subjects: 87
Study 38458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group B
Number of subjects: 87
Study 38458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group C
Number of subjects: 87
Study 38458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower neutrophil-lymphocyte ratio (NLR) (≤5.8)
Number of subjects: 87
Study 38458039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower platelet-lymphocyte ratio (PLR) (≤491.2)
Number of subjects: 87
Study 38458089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored health literacy follow-up from MI-trained COPD nurses with home visits for eight weeks and phone calls for four months after hospitalization
Number of subjects: 127
Study 38458089 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 127
Study 38458089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored health literacy follow-up from MI-trained COPD nurses
Number of subjects: 127
Study 38458208 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol plus ibuprofen
Number of subjects: 1060
Study 38458208 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol plus dexamethasone
Number of subjects: 1060
Study 38458208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus dexamethasone
Number of subjects: 1060
Study 38458208 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol plus ibuprofen plus dexamethasone
Number of subjects: 1060
Study 38458318 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver and child depression and anxiety measures
Number of subjects: 205
Study 38458318 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control assessed by the Asthma Control Test
Number of subjects: 205
Study 38458318 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics
Number of subjects: 205
Study 38458362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step conservative surgery
Number of subjects: 60
Study 38458362 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 60
Study 38458362 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step conservative surgery (subgroup type 1 class)
Number of subjects: 60
Study 38458362 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy (subgroup type 1 class)
Number of subjects: 60
Study 38458371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 489
Study 38458371 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 489
Study 38458387 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum preoperative diameter of the abdominal aorta >30 mm and/or abdominal aortic dissection
Number of subjects: 990
Study 38458387 — intervention group
Group type: COMPARATOR
Intervention: No maximum diameter >30 mm and no abdominal aortic dissection
Number of subjects: 990
Study 38458387 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum preoperative diameter of the abdominal aorta
Number of subjects: 990
Study 38458387 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal aorta dissection
Number of subjects: 990
Study 38458387 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic syndromes
Number of subjects: 990
Study 38458408 — intervention group
Group type: EXPERIMENTAL
Intervention: Double etonogestrel implant (136 mg)
Number of subjects: 72
Study 38458408 — intervention group
Group type: COMPARATOR
Intervention: Single etonogestrel implant (68 mg)
Number of subjects: 72
Study 38458558 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC intervention (telephonic, geriatrics-palliative care nurse-coaching)
Number of subjects: 60
Study 38458558 — intervention group
Group type: COMPARATOR
Intervention: Usual COPD care (control)
Number of subjects: 60
Study 38458560 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Food Delivery Intervention (HFDI) plus one 60-min virtual consultation with a diabetes educator
Number of subjects: 400
Study 38458560 — intervention group
Group type: COMPARATOR
Intervention: Consultation only
Number of subjects: 400
Study 38458577 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g cooked iron-fortified lentils (IFLs)
Number of subjects: 1195
Study 38458577 — intervention group
Group type: COMPARATOR
Intervention: 200 g cooked noniron-fortified lentils (NIFLs)
Number of subjects: 1195
Study 38458577 — intervention group
Group type: COMPARATOR
Intervention: Control group with no lentils (usual dietary intake)
Number of subjects: 1195
Study 38458584 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ischemic stroke
Number of subjects: 3902
Study 38458584 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hemorrhagic stroke
Number of subjects: 3902
Study 38458584 — intervention group
Group type: EXPERIMENTAL
Intervention: Global brain ischemia
Number of subjects: 3902
Study 38458584 — intervention group
Group type: COMPARATOR
Intervention: No neurologic complications
Number of subjects: 3902
Study 38458635 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) combined with PD-1 inhibitor toripalimab
Number of subjects: 21
Study 38458639 — intervention group
Group type: EXPERIMENTAL
Intervention: urelumab-0.1 + cetuximab-250
Number of subjects: 200
Study 38458639 — intervention group
Group type: EXPERIMENTAL
Intervention: urelumab-3 + nivolumab-3
Number of subjects: 200
Study 38458639 — intervention group
Group type: EXPERIMENTAL
Intervention: urelumab-8 + nivolumab-3
Number of subjects: 200
Study 38458639 — intervention group
Group type: EXPERIMENTAL
Intervention: urelumab-8 + nivolumab-240
Number of subjects: 200
Study 38458639 — intervention group
Group type: EXPERIMENTAL
Intervention: urelumab + nivolumab
Number of subjects: 200
Study 38458769 — intervention group
Group type: COMPARATOR
Intervention: systolic flow reversal ratio (sFRR)
Number of subjects: 15
Study 38458769 — intervention group
Group type: COMPARATOR
Intervention: average late systolic flow displacement (FD)
Number of subjects: 15
Study 38458769 — intervention group
Group type: COMPARATOR
Intervention: manual systolic rotational flow angle change (ΔsRA)
Number of subjects: 15